4D Molecular Therapeutics, Inc. Common Stock vs. Moderna, Inc. Common Stock
FDMT
4D Molecular Therapeutics, Inc. Common Stock
$13.49 -4.87%
VS MRNAModerna, Inc. Common Stock
$225.00 +14.21%
Moderna, Inc. Common Stock (MRNA) comes out ahead, leading on 2 of 2 compared factors.
Size & Scale
| FDMT | MRNA | |
|---|---|---|
| Market Cap | $745.24 million | $78.65 billion |
| Revenue (TTM) | $92.01 million | — |
| Net Income (TTM) | $-179,175,000 | — |
MRNA leads on 1 of 1 size & scale factors.
Valuation
| FDMT | MRNA | |
|---|---|---|
| Price / Book | 1.83 | — |
| Price / Sales | 8.10 | — |
FDMT and MRNA split the valuation factors evenly.
Profitability
| FDMT | MRNA | |
|---|---|---|
| Net Margin | -194.74% | — |
| Return on Equity | -43.95% | — |
FDMT and MRNA split the profitability factors evenly.
Risk & Sentiment
| FDMT | MRNA | |
|---|---|---|
| Short Interest | 0.41% | 0.01% |
MRNA leads on 1 of 1 risk & sentiment factors.
Dig deeper: FDMT overview, FDMT financials, MRNA overview, MRNA financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.